Indications
Each indication opens its study.
Metabolic Diseases
Stage of development
-
PNB-028
Pancreatic CancerCCK inhibition via the CCK-C receptor
- Molecule
- PNB-028
- Indication
- Pancreatic Cancer
- Biological action
- CCK inhibition via the CCK-C receptor
- Status
- Phase 1/2a ongoing
-
PNB-028
Colon CancerCCK inhibition via the CCK-C receptor
- Molecule
- PNB-028
- Indication
- Colon Cancer
- Biological action
- CCK inhibition via the CCK-C receptor
- Status
- Phase 1/2a ongoing
-
PNB-028
PancreatitisInhibition of pancreatic enzymes
- Molecule
- PNB-028
- Indication
- Pancreatitis
- Biological action
- Inhibition of pancreatic enzymes
- Status
- Phase 1 ready
- Target and mechanism
- CCK-C isoform-selective, irreversible antagonist binding the receptor's extracellular loop. Described by the company as the first irreversible CCK-C antagonist.
- Key findings
In nude-mouse xenograft models, PNB-028 completely inhibited growth of chemo-resistant MAC16 colon tumours and MIA PaCa pancreatic tumours. Tumours in treated animals stayed organ-confined, while untreated tumours spread to the lungs, and treated animals did not become cachectic.
Across six Colon Cancer cell lines, all expressing CCK receptors, PNB-028 inhibited cancer-cell growth without affecting normal cell lines.
In cerulein- and sincalide-induced Acute Pancreatitis models, protection was seen from 1 mg/kg, with dose-dependent reductions in inflammation and swelling.
- Development
More than 80% oral bioavailability in rats; stable in rat, dog and human liver microsomes.
Two-step synthesis from economical raw materials, purity above 99.8%; five kilograms made for regulatory studies. ICH toxicology and safety pharmacology completed.
- Intellectual property
- Patents filed in the US, Europe and rest of world; PCT application filed and granted; USPTO patent issued 28 December 2014.
Interested in a programme?
PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.
